IOVANCE BIOTHERAPEUTICS, INC. | Business Contracts

Open Market Sale Agreement dated November 18, 2022, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC (Filed With SEC on November 18, 2022)

Form of Deferred Stock Unit Notice and Deferred Stock Unit Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on August 4, 2022)

Third Amendment to the Lease Agreement, effective as of November 1, 2021, between Iovance Biotherapeutics, Inc. and 300 Rouse Boulevard, LLC (Filed With SEC on February 24, 2022)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2021 Inducement Plan (Filed With SEC on September 23, 2021)

Amended and Restated Patent License Agreement, by and between Iovance Biotherapeutics, Inc. and the National Institutes of Health (Filed With SEC on August 5, 2021)

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on August 4, 2022)

Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan (Filed With SEC on February 24, 2022)

Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Inducement Plan (Filed With SEC on September 23, 2021)

Iovance Biotherapeutics, Inc. 2021 Inducement Plan (Filed With SEC on September 23, 2021)

Form of Nonqualified Stock Option Award Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (June 2021 Retention Equity Awards) (Filed With SEC on August 5, 2021)

Form of Stock Unit Notice and Stock Unit Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (June 2021 Retention Equity Awards) (Filed With SEC on August 5, 2021)

Executive Employment Agreement, effective as of March 15, 2021, by and between Igor Bilinsky, Ph.D. and Iovance Biotherapeutics, Inc (Filed With SEC on May 6, 2021)

Executive Employment Agreement, effective as of December 14, 2020, by and between Jean-Marc Bellemin and Iovance Biotherapeutics, Inc (Filed With SEC on February 25, 2021)

Second Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on February 9, 2021)

Open Market Sale Agreement dated February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC (Filed With SEC on February 9, 2021)

First Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on February 9, 2021)

Lease Agreement dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and ARE-San Francisco No. 63, LLC (Filed With SEC on February 9, 2021)

Severance Agreement and General Release, effective July 8, 2020, between Iovance Biotherapeutics, Inc. and Timothy Morris (Filed With SEC on August 6, 2020)

Second Amendment to the Lease Agreement, effective as of June 30, 2020, between Iovance Biotherapeutics, Inc. and 300 Rouse Boulevard, LLC (Filed With SEC on August 6, 2020)

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on June 9, 2020)

Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on June 9, 2020)

Underwriting Agreement dated May 28, 2020 (Filed With SEC on May 29, 2020)

Form of Non-Qualified Stock Option Agreement under the Lion Biotechnologies, Inc. 2014 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Non-Qualified Stock Option Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Incentive Stock Option Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Incentive Stock Option Agreement under the Lion Biotechnologies, Inc. 2014 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Non-Qualified Stock Option Agreement under the Genesis Biopharma Inc. 2011 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Incentive Stock Option Agreement under the Genesis Biopharma Inc. 2011 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Description of Securities (Filed With SEC on February 25, 2020)

First Amendment to the Lease Agreement, effective as of August 20, 2019, between Iovance Biotherapeutics, Inc. and 300 Rouse Boulevard, LLC (Filed With SEC on November 4, 2019)

First Amendment to the Office Lease, effective as of June 19, 2019, between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on November 4, 2019)

Executive Employment Agreement effective as of July 18, 2019, by and between Friedrich-Reinhard Graf Finck von Finckenstein, M.D (Filed With SEC on August 1, 2019)

First Amendment to the Lease Agreement dated as of June 19, 2019, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on June 21, 2019)

Lease Agreement dated as of May 28, 2019, by and between Iovance Biotherapeutics, Inc. and 300 Rouse Boulevard, LLC (Filed With SEC on June 3, 2019)

IOVANCE BIOTHERAPEUTICS, INC. (34)